Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Inclusion Criteria: * Healthy males; * Age 30 to 65 years of age; * Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator; * Normal resting supine blood pressure and pulse or showing no clinically relevant deviation as judged by the investigator; * Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator; * All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the investigator; * Must be willing and able to communicate and participate in the whole study; * Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day); * Must provide written informed consent; * Must agree to use an adequate method of contraception Exclusion Criteria: * Females; * Subjects who have received any IMP in a clinical research study within the previous 3 months; * Subjects who are study site employees, or immediate family members of a study site or sponsor employee; * Subjects who have previously been enrolled in this study; * History of any drug or alcohol abuse in the past 2 years; * Regular alcohol consumption in males \>21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine); * Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission; * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study; * Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening; * Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator; * Positive drugs of abuse test result; * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results; * Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of \<90 mL/min using the Cockcroft-Gault equation; * History of cardiovascular, neurological, renal, hepatic, chronic respiratory or gastrointestinal disease, or clinically significant psychiatric history as judged by the investigator; * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active; * Donation or loss of greater than 400 mL of blood within the previous 3 months; * Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2 g per day paracetamol) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor; * Failure to satisfy the investigator of fitness to participate for any other reason.